NVS - Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
Introduction
Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has been spent in oncology, there is still a significant unmet need in cancer treatments.
Traditionally, cancers have been treated via surgery, chemotherapy and radiotherapy. However, such methods continue to have very limited efficacy, especially in late-stage cancers. In the case of surgery, it rarely results in complete